FirstWord Group
@firstwordgroup.com
FirstWord is a global leader in news and intelligence for the Pharma and MedTech industries. Find our services here www.firstwordpharma.com, www.firstwordhealthtech.com, and www.firstwordreports.com
FDA to remove boxed warnings from hormonal menopause treatments $BAYN $ALPMY firstwordpharma.com/story/6523840
November 11, 2025 at 4:05 AM
FDA to remove boxed warnings from hormonal menopause treatments $BAYN $ALPMY firstwordpharma.com/story/6523840
Lilly deepens ties with Insilico Medicine in new $100M deal $LLY firstwordpharma.com/story/6523757
November 10, 2025 at 11:26 PM
Lilly deepens ties with Insilico Medicine in new $100M deal $LLY firstwordpharma.com/story/6523757
Madrigal builds case for extending Rezdiffra into MASH cirrhosis $MDGL firstwordpharma.com/story/6523602
November 10, 2025 at 11:25 PM
Madrigal builds case for extending Rezdiffra into MASH cirrhosis $MDGL firstwordpharma.com/story/6523602
Anaptys scraps mid-stage study after PD-1 agonist falters in ulcerative colitis $ANAB firstwordpharma.com/story/6523703
November 10, 2025 at 11:25 PM
Anaptys scraps mid-stage study after PD-1 agonist falters in ulcerative colitis $ANAB firstwordpharma.com/story/6523703
Camurus' monthly formulation of Wegovy leads to faster weight loss $NVO $CAMX firstwordpharma.com/story/6523698
November 10, 2025 at 11:24 PM
Camurus' monthly formulation of Wegovy leads to faster weight loss $NVO $CAMX firstwordpharma.com/story/6523698
Iambic snags $100M after claiming validation for its AI platform at ESMO firstwordpharma.com/story/6523615
November 10, 2025 at 11:23 PM
Iambic snags $100M after claiming validation for its AI platform at ESMO firstwordpharma.com/story/6523615
Lilly bets on vision-restoring gene therapy in $475M MeiraGTx pact $LLY $MGTX firstwordpharma.com/story/6522501
November 10, 2025 at 5:01 PM
Lilly bets on vision-restoring gene therapy in $475M MeiraGTx pact $LLY $MGTX firstwordpharma.com/story/6522501
Late-stage study win sets up FDA filing for Cogent's bezuclastinib in GIST firstwordpharma.com/story/6522499
November 10, 2025 at 1:08 PM
Late-stage study win sets up FDA filing for Cogent's bezuclastinib in GIST firstwordpharma.com/story/6522499
Roche touts upbeat fenebrutinib readouts from two pivotal MS studies firstwordpharma.com/story/6522447
November 10, 2025 at 10:39 AM
Roche touts upbeat fenebrutinib readouts from two pivotal MS studies firstwordpharma.com/story/6522447
Rhythm's Imcivree faces extended FDA clock in hypothalamic obesity bid $RYTM firstwordpharma.com/story/6518035
November 7, 2025 at 4:47 PM
Rhythm's Imcivree faces extended FDA clock in hypothalamic obesity bid $RYTM firstwordpharma.com/story/6518035
Noom rolls out AI tools to combat diabetes
firstwordhealthtech.com/story/6517836
firstwordhealthtech.com/story/6517836
November 7, 2025 at 4:17 PM
Noom rolls out AI tools to combat diabetes
firstwordhealthtech.com/story/6517836
firstwordhealthtech.com/story/6517836
Synchron bags $200M to advance thought-control tech
firstwordhealthtech.com/story/6517684
firstwordhealthtech.com/story/6517684
November 7, 2025 at 4:16 PM
Synchron bags $200M to advance thought-control tech
firstwordhealthtech.com/story/6517684
firstwordhealthtech.com/story/6517684
Patient hospitalised after receiving Intellia's CRISPR therapy dies firstwordpharma.com/story/6518005
November 7, 2025 at 11:26 AM
Patient hospitalised after receiving Intellia's CRISPR therapy dies firstwordpharma.com/story/6518005
Eledon pursues Phase III bid for kidney transplant drug despite mid-stage failure firstwordpharma.com/story/6517914
November 7, 2025 at 10:09 AM
Eledon pursues Phase III bid for kidney transplant drug despite mid-stage failure firstwordpharma.com/story/6517914
Weight-loss drugs head latest batch of FDA priority voucher recipients firstwordpharma.com/story/6517840
November 7, 2025 at 4:13 AM
Weight-loss drugs head latest batch of FDA priority voucher recipients firstwordpharma.com/story/6517840
Lilly, Novo to discount weight-loss drugs in MFN pricing deal with Trump $LLY $NVO firstwordpharma.com/story/6516824
November 6, 2025 at 10:06 PM
Lilly, Novo to discount weight-loss drugs in MFN pricing deal with Trump $LLY $NVO firstwordpharma.com/story/6516824
US okays Darzalex Faspro for high-risk smouldering myeloma $JNJ firstwordpharma.com/story/6517750
November 6, 2025 at 10:06 PM
US okays Darzalex Faspro for high-risk smouldering myeloma $JNJ firstwordpharma.com/story/6517750
J&J's Caplyta wins FDA nod for depression add-on use $JNJ firstwordpharma.com/story/6517700
November 6, 2025 at 10:05 PM
J&J's Caplyta wins FDA nod for depression add-on use $JNJ firstwordpharma.com/story/6517700
Novo again ups the stakes after Pfizer reportedly matches $10B bid for Metsera firstwordpharma.com/story/6516679
November 6, 2025 at 5:50 PM
Novo again ups the stakes after Pfizer reportedly matches $10B bid for Metsera firstwordpharma.com/story/6516679
Lilly readies to take amylin-based obesity drug into Phase III next month $LLY firstwordpharma.com/story/6516690
November 6, 2025 at 5:36 PM
Lilly readies to take amylin-based obesity drug into Phase III next month $LLY firstwordpharma.com/story/6516690
Neuralink challenger Precision Neuroscience advances BCI tech with new investment firstwordhealthtech.com/story/6516406
November 6, 2025 at 2:56 PM
Neuralink challenger Precision Neuroscience advances BCI tech with new investment firstwordhealthtech.com/story/6516406
Pfizer said to match Novo's $10B bid for Metsera: report firstwordpharma.com/story/6516679
November 6, 2025 at 10:48 AM
Pfizer said to match Novo's $10B bid for Metsera: report firstwordpharma.com/story/6516679
With 2030 ambitions in view, AstraZeneca’s quarterly revenue passes $15B for first time firstwordpharma.com/story/6516661
November 6, 2025 at 9:29 AM
With 2030 ambitions in view, AstraZeneca’s quarterly revenue passes $15B for first time firstwordpharma.com/story/6516661
MoonLake to meet with FDA for sonelokimab HS submission, raises $75M $MLTX firstwordpharma.com/story/6516526
November 5, 2025 at 10:48 PM
MoonLake to meet with FDA for sonelokimab HS submission, raises $75M $MLTX firstwordpharma.com/story/6516526
MoonLake to meet with FDA for sonelokimab HS submission, raises $75M $MLTX firstwordpharma.com/story/6516526
November 5, 2025 at 10:49 PM
MoonLake to meet with FDA for sonelokimab HS submission, raises $75M $MLTX firstwordpharma.com/story/6516526